Universitätsklinikum Schleswig-Holstein (UKSH)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study (2021) Kaehler KC, Gutzmer R, Meier F, Zimmer L, Heppt M, Gesierich A, Thoms KM, et al. Journal article Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference (2021) Untch M, Fasching P, Brucker SY, Budach W, Denkert C, Haidinger R, Huober J, et al. Journal article, Review article Comparative transcriptomics of immune checkpoint inhibitor myocarditis identifies guanylate binding protein 5 and 6 dysregulation (2021) Finke D, Heckmann MB, Salatzki J, Riffel J, Herpel E, Heinzerling L, Meder B, et al. Journal article Factors influencing the adjuvant therapy decision: Results of a real-world multicenter data analysis of 904 melanoma patients (2021) Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, et al. Journal article Real World Evidence on the effectiveness of ustekinumab in Crohn's Disease: Induction phase results from the prospective, observational RUN-CD Study (2021) Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, et al. Conference contribution EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2021) Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn B, Barinoff J, et al. Conference contribution BACH1 and HIF1 alpha predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) Vladimirova V, Schneeweiss A, Jackisch C, Weber KE, Denkert C, Schmatloch S, Karn T, et al. Conference contribution Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials (2021) Furlanetto J, Denkert C, Untch M, Sinn B, Lederer B, Schneeweiss A, Mueller V, et al. Conference contribution Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial (2021) Llop-Guevara A, Vladimirova V, Schneeweiss A, Villacampa G, Karn T, Zahm DM, Herencia-Ropero A, et al. Journal article, Original article Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from pd-l1 inhibition in women with early triple-negative breast cancer (2021) Sinn BV, Loibl S, Hanusch CA, Zahm DM, Sinn HP, Untch M, Weber K, et al. Journal article